Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calcitonin oral - Enteris BioPharma

Drug Profile

Calcitonin oral - Enteris BioPharma

Alternative Names: Calcitonin-salmon [rDNA origin] delayed release tablets; Oral recombinant salmon calcitonin - Tarsa Therapeutics; Ostora; rsCT; Salmon calcitonin oral - Tarsa Therapeutics; sCT oral; TBRIA

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unigene Laboratories
  • Developer Enteris BioPharma; R-Pharm; Tarsa Therapeutics
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Postmenopausal osteoporosis
  • No development reported Osteoarthritis

Most Recent Events

  • 09 Apr 2021 No development reported - Preregistration for Postmenopausal osteoporosis in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis(Combination therapy) in USA (PO)
  • 19 Oct 2015 Planned Prescription Drug User Fee Act (PDUFA) date for Postmenopausal osteoporosis in USA (PO) is 2016-05-30
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top